Invivyd, INC. (IVVD) — SEC Filings

Overview

Invivyd, INC. (IVVD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 6, 2026: Invivyd, Inc. filed an Annual Report to Security Holders (ARS) on April 6, 2026, for the period ending December 31, 2025. The company, with CIK 0001832038, is involved in Biological Products, excluding Diagnostic Substances. The filing includes a 10-K report for the fiscal year 2025.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 2 bearish, 46 neutral, 2 mixed. The dominant filing sentiment for Invivyd, INC. is neutral.

Filing Type Overview

Invivyd, INC. (IVVD) has filed 38 8-K, 1 ARS, 6 10-Q, 1 DEF 14A, 1 SC 13D/A, 3 SC 13G/A with the SEC between May 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• 8-K Filing — 8-K · Apr 9, 2026
• Invivyd Files Annual Report for FY 2025 — ARS · Apr 6, 2026 Risk: low
  Invivyd, Inc. filed an Annual Report to Security Holders (ARS) on April 6, 2026, for the period ending December 31, 2025. The company, with CIK 0001832038, is i
• Invivyd, Inc. Files 8-K — 8-K · Dec 23, 2025 Risk: low
  Invivyd, Inc. filed an 8-K on December 23, 2025, reporting other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is i
• 8-K Filing — 8-K · Nov 24, 2025
• 8-K Filing — 8-K · Nov 19, 2025
• Invivyd's Revenue Surges, But Going Concern Doubts Linger Amid R&D Shift — 10-Q · Nov 6, 2025 Risk: high
  Invivyd, Inc. reported a significant increase in product revenue, reaching $36.2 million for the nine months ended September 30, 2025, a substantial rise from $
• Invivyd, Inc. Files 8-K Report — 8-K · Oct 30, 2025 Risk: low
  On October 30, 2025, Invivyd, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financ
• Invivyd, Inc. Files 8-K — 8-K · Oct 6, 2025 Risk: low
  Invivyd, Inc. filed an 8-K on October 6, 2025, reporting other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is inc
• Invivyd, Inc. Files 8-K: Officer/Director Changes & More — 8-K · Sep 24, 2025 Risk: medium
  Invivyd, Inc. filed an 8-K on September 24, 2025, reporting on events as of September 22, 2025. The filing covers the departure of directors or certain officers
• Invivyd, Inc. Files 8-K for Material Definitive Agreement — 8-K · Aug 22, 2025 Risk: medium
  On August 20, 2025, Invivyd, Inc. entered into a material definitive agreement. The company, formerly known as Adagio Therapeutics, Inc., is based in Waltham, M
• Invivyd, Inc. Files 8-K on Financials and Operations — 8-K · Aug 14, 2025 Risk: low
  On August 14, 2025, Invivyd, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with oth
• Invivyd's Revenue Soars 420% on PEMGARDA, But Going Concern Looms — 10-Q · Aug 14, 2025 Risk: high
  Invivyd, Inc. (IVVD) reported a significant increase in product revenue, reaching $11.786 million for the three months ended June 30, 2025, up from $2.264 milli
• Invivyd, Inc. Files 8-K Report — 8-K · Jul 2, 2025 Risk: low
  Invivyd, Inc. filed an 8-K on July 2, 2025, reporting other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is incorp
• Invivyd, Inc. Files 8-K — 8-K · Jun 26, 2025 Risk: low
  Invivyd, Inc. filed an 8-K on June 26, 2025, reporting other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is incor
• Invivyd, Inc. Files 8-K on Security Holder Vote Matters — 8-K · May 20, 2025 Risk: low
  Invivyd, Inc. filed an 8-K on May 20, 2025, to report on the submission of matters to a vote of its security holders. The filing does not contain specific detai
• Invivyd, Inc. Files 8-K on Financials and Operations — 8-K · May 15, 2025 Risk: low
  Invivyd, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition, as well as other events. The filing also includes fi
• Invivyd, Inc. Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
  Invivyd, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Adagio Therapeutics, Inc., is involved in biological products.
• Invivyd, Inc. Files 8-K — 8-K · May 12, 2025 Risk: low
  Invivyd, Inc. filed an 8-K on May 12, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific financial det
• Invivyd, Inc. Faces Delisting Concerns — 8-K · Apr 25, 2025 Risk: high
  Invivyd, Inc. (formerly Adagio Therapeutics, Inc.) filed an 8-K on April 25, 2025, reporting a notice of delisting or failure to satisfy a continued listing rul
• Invivyd, Inc. Files 8-K for Material Agreement — 8-K · Apr 21, 2025 Risk: medium
  Invivyd, Inc. announced on April 18, 2025, the entry into a material definitive agreement and the creation of a direct financial obligation. The company, former
• Invivyd Files 2025 Proxy Statement — DEF 14A · Apr 7, 2025 Risk: low
  Invivyd, Inc. filed its definitive proxy statement (DEF 14A) on April 7, 2025, for the fiscal year ending December 31, 2024. The company, formerly known as Adag
• Invivyd, Inc. Files 8-K on Officer/Director Changes — 8-K · Mar 26, 2025 Risk: medium
  Invivyd, Inc. filed an 8-K on March 26, 2025, reporting on events as of March 22, 2025. The filing covers the departure of directors or certain officers, the el
• Invivyd, Inc. Files 8-K on Financials — 8-K · Mar 20, 2025 Risk: low
  Invivyd, Inc. filed an 8-K on March 20, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and
• Invivyd, Inc. Files 8-K — 8-K · Mar 5, 2025 Risk: low
  Invivyd, Inc. filed an 8-K on March 5, 2025, reporting other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is incor
• Invivyd, Inc. Files 8-K with Financials — 8-K · Feb 24, 2025 Risk: low
  Invivyd, Inc. filed an 8-K on February 24, 2025, reporting events as of February 21, 2025. The filing primarily concerns financial statements and exhibits, with
• Invivyd, Inc. Files 8-K on Financials and Other Events — 8-K · Feb 3, 2025 Risk: low
  Invivyd, Inc. filed an 8-K on February 3, 2025, reporting on its Results of Operations and Financial Condition, Other Events, and Financial Statements and Exhib
• Invivyd, Inc. Files 8-K — 8-K · Jan 27, 2025 Risk: low
  Invivyd, Inc. filed an 8-K on January 27, 2025, to report other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is in
• Invivyd, Inc. Files 8-K — 8-K · Jan 10, 2025 Risk: low
  Invivyd, Inc. filed an 8-K on January 10, 2025, reporting other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is in
• Invivyd, Inc. Files 8-K on Delisting Concerns — 8-K · Dec 27, 2024 Risk: high
  Invivyd, Inc. filed an 8-K on December 27, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as
• Polaris Venture Partners V amends Invivyd stake — SC 13D/A · Dec 12, 2024 Risk: medium
  On December 12, 2024, Polaris Venture Partners V, L.P. filed an SC 13D/A amendment regarding Invivyd, Inc. (formerly Adagio Therapeutics, Inc.). The filing indi
• Invivyd Reports Director Changes and Compensation Updates — 8-K · Dec 2, 2024 Risk: medium
  Invivyd, Inc. filed an 8-K on November 27, 2024, reporting changes in its board of directors and executive compensation arrangements. The filing indicates a dep
• Invivyd, Inc. Files 8-K on Financials and Operations — 8-K · Nov 14, 2024 Risk: low
  Invivyd, Inc. filed an 8-K on November 14, 2024, reporting on its results of operations and financial condition, other events, and financial statements. The fil
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Invivyd, Inc. Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: medium
  Invivyd, Inc. (formerly Adagio Therapeutics, Inc.) filed its 10-Q for the period ending September 30, 2024. The company, incorporated in Delaware, operates in t
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G/A Filing — SC 13G/A · Nov 8, 2024
• Invivyd, Inc. Files 8-K — 8-K · Oct 29, 2024 Risk: low
  Invivyd, Inc. filed an 8-K on October 29, 2024, reporting on its results of operations, other events, and financial statements. The company, formerly known as A
• Invivyd, Inc. Files 8-K — 8-K · Sep 23, 2024 Risk: low
  Invivyd, Inc. filed an 8-K on September 23, 2024, reporting other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is
• Invivyd, Inc. Files 8-K Report — 8-K · Sep 6, 2024 Risk: low
  Invivyd, Inc. filed an 8-K on September 6, 2024, to report other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is i
• Invivyd, Inc. Files 8-K — 8-K · Sep 4, 2024 Risk: low
  Invivyd, Inc. filed an 8-K on September 4, 2024, to report other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is i
• Invivyd, Inc. Files 8-K — 8-K · Sep 3, 2024 Risk: low
  Invivyd, Inc. filed an 8-K on September 3, 2024, reporting other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is i
• Invivyd, Inc. Announces CMO Departure and Interim Appointment — 8-K · Aug 27, 2024 Risk: medium
  On August 27, 2024, Invivyd, Inc. filed an 8-K report detailing the resignation of Dr. David M. Apelian from his role as Chief Medical Officer, effective August
• Invivyd, Inc. Files 8-K on Operations and Financials — 8-K · Aug 14, 2024 Risk: low
  Invivyd, Inc. filed an 8-K on August 14, 2024, reporting on its results of operations, financial condition, and other events. The filing also includes financial
• Invivyd, Inc. Files Q2 2024 10-Q Report — 10-Q · Aug 14, 2024 Risk: medium
  Invivyd, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Adagio Therapeutics, Inc., reported on its financial activities
• Invivyd, Inc. Files 8-K — 8-K · Jun 14, 2024 Risk: low
  Invivyd, Inc. filed an 8-K on June 14, 2024, to report other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is incor
• Invivyd Appoints New CMO and COO — 8-K · May 31, 2024 Risk: medium
  Invivyd, Inc. announced on May 30, 2024, the appointment of Dr. Patrick Gilmore as Chief Medical Officer and Dr. David Apelian as Chief Operating Officer. The c
• Invivyd, Inc. Files 8-K: Voting Matters & Financials — 8-K · May 22, 2024 Risk: low
  Invivyd, Inc. (formerly Adagio Therapeutics, Inc.) filed an 8-K on May 22, 2024, reporting on matters submitted to a vote of security holders, Regulation FD dis
• Invivyd, Inc. Files 8-K on Operations and Financials — 8-K · May 9, 2024 Risk: low
  Invivyd, Inc. filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition, as well as other events. The filing also includes fin
• Invivyd, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: medium
  Invivyd, Inc. (IVVD) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Invivyd, Inc. (formerly Adagio Therapeutics, Inc.) filed a 10-Q report for the
• Invivyd, Inc. Files 8-K — 8-K · May 7, 2024 Risk: low
  Invivyd, Inc. filed an 8-K on May 7, 2024, reporting on other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is inco

Risk Profile

Risk Assessment: Of IVVD's 44 recent filings, 4 were flagged as high-risk, 12 as medium-risk, and 28 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Invivyd, INC.'s most recent 10-Q filing (Nov 6, 2025):

• Revenue: $36,219,000
• Net Income: -$43,005,000
• EPS: N/A
• Debt-to-Equity: 0.49
• Cash Position: $84,967,000
• Operating Margin: -118.8%
• Total Assets: $139,158,000
• Total Debt: $46,090,000

Key Executives

• Jonathan Flint
• Terrance McGuire
• Dr. David M. Apelian
• Dr. Erin Coller
• Dr. Patrick Gilmore
• Dr. David Apelian

Industry Context

The biotechnology sector, particularly in infectious disease, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Invivyd compete in a dynamic landscape where rapid scientific advancement and the emergence of new pathogens necessitate continuous innovation. The COVID-19 therapeutic and preventative market remains competitive, with established players and emerging biotechs vying for market share.

Top Tags

sec-filing (12) · 8-K (6) · 8-k (6) · financials (5) · regulatory-filing (5) · biotech (5) · filing (4) · financial-reporting (4) · 10-Q (4) · corporate-update (4)

Key Numbers

• Fiscal Year End: 2025-12-31 — Period covered by the ARS filing
• Product revenue, net: $36.2M — Increased from $11.6M for the nine months ended September 30, 2024
• Net loss: $41.4M — For the nine months ended September 30, 2025, an improvement from $151.5M in 2024
• Accumulated deficit: $943.4M — As of September 30, 2025, indicating significant historical losses
• Cash and cash equivalents: $85.0M — As of September 30, 2025, up from $69.3M at December 31, 2024
• Research and development expenses: $28.3M — For the nine months ended September 30, 2025, a decrease from $119.3M in 2024
• Proceeds from underwritten public offering: $54.0M — Net proceeds received during the nine months ended September 30, 2025
• Common shares outstanding: 214,409,450 — As of September 30, 2025, significantly increased from 119,835,162 at December 31, 2024
• Report Date: 20250820 — The filing reports events as of this date.
• SEC File Number: 001-40703 — Identifies the company's filing with the SEC.
• Total revenue: $23.090M — for six months ended June 30, 2025, significantly up from $2.264M in 2024
• IRS Employer Identification No.: 85-1403134 — Company's tax identification number
• Reporting Period End: 20250331 — Quarterly financial reporting
• Filing Date: 20250515 — Date the report was submitted
• Commission File Number: 001-40703 — Identifies the company's filing with the SEC.

Frequently Asked Questions